Restoration of lymphatic function in postsurgical lymphedema with lymph node transfer

通过淋巴结转移恢复术后淋巴水肿的淋巴功能

基本信息

  • 批准号:
    9185953
  • 负责人:
  • 金额:
    $ 19.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-12-01 至 2017-11-30
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): This proposal is significant because we aim to develop novel treatments for lymphedema, a common and morbid complication of cancer treatment that results in chronic swelling, recurrent infections, and immune dysfunction. Recent clinical studies have reported decreased swelling and symptomatic relief after lymph node transfer (LNT) to the affected limb. To study the mechanisms of this process, we have developed a mouse model of LNT and have shown that the lymphatic vessels of the lymph node spontaneously reconnect with the lymphatics of the recipient site thereby restoring lymphatic circulation. However, although these results are promising, it remains unclear if immunologic function is restored after LNT. This gap in our knowledge is important because understanding the mechanisms by which LNT regulates immune function and microenvironmental changes is a necessary step for improving these outcomes. Our proposed study will address this gap and will therefore break new ground in the treatment of lymphedema. Our approach is innovative because we have developed an inducible mouse model of lymphedema in which tissue lymphatics can be selectively ablated using diphtheria toxin. This enables us to study immune function after LNT in a clinically relevant model and test the central hypothesis that lymphatic regeneration after LNT restores immune function and promotes resolution of tumorigenic microenvironmental changes. Aim 1: Determine how LNT restores immune function. This aim will test the hypothesis that innate and adaptive immune function is restored after LNT. The rationale for these studies is based on the fact that patients who have undergone lymph node dissection or suffer from lymphedema have impaired antibody response and are at increased risk for infections. Aim 2: Determine how LNT regulates lymphatic injury induced microenvironmental changes and tumor recurrence. This aim will test the hypothesis that LNT decreases activation of tumorigenic microenvironmental changes known to occur after lymphatic injury. This hypothesis is based on the rationale that 1) Patients with breast cancer are at high risk for loco-regional recurrence; 2) Lymphatic injury increases expression of tumorigenic pathways including interleukin 6 as well as macrophages and Treg infiltration; and 3) Previous animal studies have shown that lymphatic injury increases the growth/metastasis of breast cancers. We will test our mouse model of LNT together with microscopic orthotopic and heterotopic breast tumor implants to determine how restoration of immune responses by LNT regulate growth of local recurrence or development of a new primary cancer. As a result of these studies, we expect to further our understanding of the mechanisms by which lymphatic injury regulates tumor growth/spread and how these changes are modulated by LNT. At the conclusion of the proposed study we expect to understand the mechanisms that regulate impaired immune function and promote tumorigenic environmental changes after lymphatic injury and how these responses are altered by LNT. These studies are therefore not only important not to patients with lymphedema but will also increase our general understanding of how the lymphatic system can regulate tumor growth.
 描述(通过应用程序提供):该建议很重要,因为我们旨在开发淋巴水肿的新型治疗方法,淋巴水肿是癌症治疗的常见和病态并发症,导致慢性肿胀,复发性感染和免疫功能障碍。最近的临床研究报告说,淋巴结(LNT)向受影响的肢体转移后肿胀和交响乐的减少。为了研究此过程的机制,我们开发了LNT的小鼠模型,并表明淋巴结的淋巴管赞助与受体部位的淋巴机重新连接,从而恢复淋巴循环。但是,尽管有望确定这些结果,但尚不清楚LNT后是否还原免疫功能。我们知识上的这一差距很重要,因为了解LNT调节免疫功能和微环境变化的机制是改善这些结果的必要步骤。我们提出的研究将解决这一差距,因此将在治疗淋巴水肿方面打破新的基础。我们的方法具有创新性,因为我们开发了一种可诱导的小鼠淋巴水肿模型,其中可以使用白喉毒素选择性地消融组织淋巴管。这使我们能够在临床相关模型中研究LNT后的免疫功能,并检验中心假设,即LNT后LNT后淋巴再生恢复了免疫功能并促进了肿瘤性微环境变化的分辨率。目标1:确定LNT如何恢复免疫学功能。该目标将检验以下假设:LNT之后恢复了先天和适应性免疫学功能。这些研究的理由是基于以下事实:接受淋巴结清扫或患有淋巴水肿的患者抗体反应受损,并且感染风险增加。目标2:确定LNT如何调节淋巴损伤引起的微环境变化和肿瘤复发。该目标将检验以下假设:LNT降低了淋巴损伤后已知发生的肿瘤微环境变化的激活。该假设是基于这样的理由:1)患有乳腺癌的患者有现代区域复发的高风险; 2)淋巴损伤增加了包括白介素6以及巨噬细胞和Treg浸润的肿瘤途径的表达; 3)先前的动物研究表明,淋巴损伤会增加乳腺癌的生长/转移。我们将测试LNT的小鼠模型以及微小的原位和异位乳腺肿瘤,以确定LNT通过LNT调节新原发性癌症的局部复发或发育的恢复。这些研究的结果,我们希望进一步了解淋巴损伤调节肿瘤生长/扩散的机制,以及如何通过LNT调节这些变化。在拟议的研究结束时,我们希望了解调节免疫功能受损的机制,并在淋巴损伤后促进肿瘤性环境变化,以及LNT如何改变这些反应。因此,这些研究不仅对淋巴水肿的患者不重要,而且还将增加我们对淋巴系统如何调节肿瘤生长的一般理解。

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Babak J Mehrara其他文献

Babak J Mehrara的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Babak J Mehrara', 18)}}的其他基金

Role of epidermis in regulating inflammatory skin manifestations of post-surgical lymphedema
表皮在调节术后淋巴水肿炎症性皮肤表现中的作用
  • 批准号:
    10606927
  • 财政年份:
    2022
  • 资助金额:
    $ 19.13万
  • 项目类别:
Molecular mechanisms of age-related lymphatic dysfunction
年龄相关淋巴功能障碍的分子机制
  • 批准号:
    10538995
  • 财政年份:
    2022
  • 资助金额:
    $ 19.13万
  • 项目类别:
Molecular mechanisms of age-related lymphatic dysfunction
年龄相关淋巴功能障碍的分子机制
  • 批准号:
    10665795
  • 财政年份:
    2022
  • 资助金额:
    $ 19.13万
  • 项目类别:
Mechanisms of fibrosis and lymphatic dysfunction in post-surgical lymphedema
术后淋巴水肿纤维化和淋巴功能障碍的机制
  • 批准号:
    8532029
  • 财政年份:
    2012
  • 资助金额:
    $ 19.13万
  • 项目类别:
Mechanisms of fibrosis in post-surgical lymphedema
术后淋巴水肿纤维化的机制
  • 批准号:
    10063531
  • 财政年份:
    2012
  • 资助金额:
    $ 19.13万
  • 项目类别:
Mechanisms of fibrosis and lymphatic dysfunction in post-surgical lymphedema
术后淋巴水肿纤维化和淋巴功能障碍的机制
  • 批准号:
    8372995
  • 财政年份:
    2012
  • 资助金额:
    $ 19.13万
  • 项目类别:
Mechanisms of fibrosis and lymphatic dysfunction in post-surgical lymphedema
术后淋巴水肿纤维化和淋巴功能障碍的机制
  • 批准号:
    8695460
  • 财政年份:
    2012
  • 资助金额:
    $ 19.13万
  • 项目类别:
Mechanisms of fibrosis and lymphatic dysfunction in post-surgical lymphedema
术后淋巴水肿纤维化和淋巴功能障碍的机制
  • 批准号:
    9094645
  • 财政年份:
    2012
  • 资助金额:
    $ 19.13万
  • 项目类别:
Surgical Oncology Research Training Grant
肿瘤外科研究培训补助金
  • 批准号:
    10674795
  • 财政年份:
    1984
  • 资助金额:
    $ 19.13万
  • 项目类别:
Surgical Oncology Research Training Grant
肿瘤外科研究培训补助金
  • 批准号:
    10456823
  • 财政年份:
    1984
  • 资助金额:
    $ 19.13万
  • 项目类别:

相似国自然基金

基于磁共振APT成像的乳腺癌新辅助治疗敏感性预测研究
  • 批准号:
    82302153
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
机器学习辅助按需设计多酶活性纳米酶用于糖尿病足溃疡治疗研究
  • 批准号:
    32371465
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
基于多时序CT影像与病理WSI的非小细胞肺癌新辅助免疫治疗疗效预测研究
  • 批准号:
    82360356
  • 批准年份:
    2023
  • 资助金额:
    32 万元
  • 项目类别:
    地区科学基金项目
基于深度学习和肿瘤-免疫-间质生物模型的肿瘤药物联合治疗疗效预测和辅助决策研究
  • 批准号:
    72374119
  • 批准年份:
    2023
  • 资助金额:
    40 万元
  • 项目类别:
    面上项目
类病毒结构纳米载体辅助A型肉毒毒素膀胱内递送治疗膀胱过度活动症的设计和应用研究
  • 批准号:
    82300874
  • 批准年份:
    2023
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Cellular mechanisms for the degeneration and aging of human rotator cuff tears
人类肩袖撕裂变性和衰老的细胞机制
  • 批准号:
    10648672
  • 财政年份:
    2023
  • 资助金额:
    $ 19.13万
  • 项目类别:
Investigating metabolism and DNA damage repair in uropathogenic Escherichia coli fluoroquinolone persisters
研究泌尿道致病性大肠杆菌氟喹诺酮类持续存在的代谢和 DNA 损伤修复
  • 批准号:
    10747651
  • 财政年份:
    2023
  • 资助金额:
    $ 19.13万
  • 项目类别:
Validation of the joint-homing and drug delivery attributes of novel peptides in a mouse arthritis model
在小鼠关节炎模型中验证新型肽的关节归巢和药物递送特性
  • 批准号:
    10589192
  • 财政年份:
    2023
  • 资助金额:
    $ 19.13万
  • 项目类别:
Design of a Novel Nanocarrier Technology to Drug-Load CAR T cells
用于载药 CAR T 细胞的新型纳米载体技术的设计
  • 批准号:
    10734365
  • 财政年份:
    2023
  • 资助金额:
    $ 19.13万
  • 项目类别:
Elucidating a novel WNT4 regulatory axis as a driver of gynecologic cancer health disparities
阐明新的 WNT4 调节轴作为妇科癌症健康差异的驱动因素
  • 批准号:
    10773991
  • 财政年份:
    2023
  • 资助金额:
    $ 19.13万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了